Evidence map›Paper›PMID 34591687›Full record

ArticleThe American journal of sports medicine2021

An Anterior Cruciate Ligament Rupture Increases Levels of Urine N-terminal Cross-linked Telopeptide of Type I Collagen, Urine C-terminal Cross-linked Telopeptide of Type II Collagen, Serum Aggrecan ARGS Neoepitope, and Serum Tumor Necrosis Factor-α.

Frans J A Hagemans, Staffan Larsson, Max Reijman, Richard B Frobell, Andre Struglics, Duncan E Meuffels

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The American journal of sports medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Frans J A HagemansDepartment of Orthopaedics and Sports Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands.
Staffan LarssonDepartment of Clinical Sciences, Faculty of Medicine, Lund University, Lund, Sweden.
Max ReijmanDepartment of Orthopaedics and Sports Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands.
Richard B FrobellDepartment of Clinical Sciences, Faculty of Medicine, Lund University, Lund, Sweden.
Andre StruglicsDepartment of Clinical Sciences, Faculty of Medicine, Lund University, Lund, Sweden.
Duncan E MeuffelsDepartment of Orthopaedics and Sports Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0002-5372-6003
Erasmus MC · NLLund University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAn anterior cruciate ligament (ACL) rupture results in an increased risk of developing knee osteoarthritis (OA) at an early age. Before clinical signs become apparent, the OA process has already been initiated. Therefore, it is important to look at the cascade of changes, such as the activity of cytokines and proteases, which might be associated with the later development of OA. PURPOSE: To compare biomarker levels in patients with a recent ACL rupture with those in controls with a healthy knee and to monitor biomarker levels over 2 years after an ACL rupture. STUDY

designDescriptive laboratory study.

methodsPatients were enrolled after an ACL tear was identified. Serum and urine samples were collected at the time of enrollment in the study (3-25 weeks after the injury) and then at 14 and 27 months after the injury between January 2009 and November 2010. Reference samples were obtained from participants with healthy knees. The following biomarkers were measured with immunological assays: aggrecan ARGS neoepitope (ARGS-aggrecan), tumor necrosis factor-α (TNF-α), interferon-γ, interleukin (IL)-8, IL-10, IL-13, N-terminal cross-linked telopeptide of type I collagen (NTX-I), and C-terminal cross-linked telopeptide of type II collagen (CTX-II).

resultsSamples were collected from 152 patients with an acute ACL rupture, who had a median age of 25 years (interquartile range [IQR], 21-32 years). There were 62 urine reference samples (median age, 25 years [IQR, 22-36 years]) and 26 serum reference samples (median age, 35 years [IQR, 24-39 years]). At a median of 11 weeks (IQR, 7-17 weeks) after trauma, serum levels of both ARGS-aggrecan and TNF-α were elevated 1.5-fold (

conclusionIn the first few months after an ACL injury, there was a measurable increase in serum levels of ARGS-aggrecan and TNF-α as well as urine levels of NTX-I and CTX-II. These markers remained high compared with those of controls with healthy knees at 2-year follow-up.

Indexed as

Anterior Cruciate Ligament InjuriesTumor Necrosis Factor-alphaAdultAggrecansAnterior Cruciate LigamentBiomarkersCollagen Type ICollagen Type IIHumansSynovial FluidYoung AdultAggrecansBiomarkersCollagen Type ICollagen Type IITumor Necrosis Factor-alphaACL injuryaggrecanbiomarkersCTX-IINTX-ITNF-α

Identifiers

PMID34591687
PMCPMC8573615
OpenAlexW3204552076

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.